These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20370714)

  • 1. Updating the chemistry and biology of cannabinoid CB2 receptor-specific inverse agonists.
    Lunn CA
    Curr Top Med Chem; 2010; 10(8):768-78. PubMed ID: 20370714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous optimization of potency, selectivity and physicochemical properties for cannabinoid CB(2) ligands.
    Worm K; Dolle RE
    Curr Pharm Des; 2009; 15(29):3345-66. PubMed ID: 19860684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of cannabinoid CB
    Salort G; Álvaro-Bartolomé M; García-Sevilla JA
    Psychopharmacology (Berl); 2017 Mar; 234(6):925-941. PubMed ID: 28127623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabidiol skews biased agonism at cannabinoid CB
    Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
    Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of novel cannabinoid receptors.
    Kreitzer FR; Stella N
    Pharmacol Ther; 2009 May; 122(2):83-96. PubMed ID: 19248809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel class of selective human CB1 inverse agonists.
    Foloppe N; Allen NH; Bentley CH; Brooks TD; Kennett G; Knight AR; Leonardi S; Misra A; Monck NJ; Sellwood DM
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1199-206. PubMed ID: 18083560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CB₂: therapeutic target-in-waiting.
    Atwood BK; Straiker A; Mackie K
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jul; 38(1):16-20. PubMed ID: 22197668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors.
    Reggio PH
    Curr Pharm Des; 2003; 9(20):1607-33. PubMed ID: 12871061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
    Behrenswerth A; Volz N; Toräng J; Hinz S; Bräse S; Müller CE
    Bioorg Med Chem; 2009 Apr; 17(7):2842-51. PubMed ID: 19278853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors.
    Pazos MR; Mohammed N; Lafuente H; Santos M; Martínez-Pinilla E; Moreno E; Valdizan E; Romero J; Pazos A; Franco R; Hillard CJ; Alvarez FJ; Martínez-Orgado J
    Neuropharmacology; 2013 Aug; 71():282-91. PubMed ID: 23587650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
    Han S; Thatte J; Buzard DJ; Jones RM
    J Med Chem; 2013 Nov; 56(21):8224-56. PubMed ID: 23865723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages.
    Tolón RM; Núñez E; Pazos MR; Benito C; Castillo AI; Martínez-Orgado JA; Romero J
    Brain Res; 2009 Aug; 1283():148-54. PubMed ID: 19505450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching cannabinoid response from CB(2) agonists to FAAH inhibitors.
    Tourteau A; Leleu-Chavain N; Body-Malapel M; Andrzejak V; Barczyk A; Djouina M; Rigo B; Desreumaux P; Chavatte P; Millet R
    Bioorg Med Chem Lett; 2014 Mar; 24(5):1322-6. PubMed ID: 24508127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
    Pertwee RG
    Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the CB2 receptor for immune modulation.
    Lunn CA; Reich EP; Bober L
    Expert Opin Ther Targets; 2006 Oct; 10(5):653-63. PubMed ID: 16981823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.
    El Bakali J; Muccioli GG; Renault N; Pradal D; Body-Malapel M; Djouina M; Hamtiaux L; Andrzejak V; Desreumaux P; Chavatte P; Lambert DM; Millet R
    J Med Chem; 2010 Nov; 53(22):7918-31. PubMed ID: 20979417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
    McHugh D; Tanner C; Mechoulam R; Pertwee RG; Ross RA
    Mol Pharmacol; 2008 Feb; 73(2):441-50. PubMed ID: 17965195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoids for the treatment of inflammation.
    Ashton JC
    Curr Opin Investig Drugs; 2007 May; 8(5):373-84. PubMed ID: 17520866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
    De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
    J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicinal Chemistry, Pharmacology, and Potential Therapeutic Benefits of Cannabinoid CB2 Receptor Agonists.
    Aghazadeh Tabrizi M; Baraldi PG; Borea PA; Varani K
    Chem Rev; 2016 Jan; 116(2):519-60. PubMed ID: 26741146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.